CN110420222A - A kind of rhodioside joint mesenchymal stem cell injection and preparation method thereof for cardiomyopathy - Google Patents
A kind of rhodioside joint mesenchymal stem cell injection and preparation method thereof for cardiomyopathy Download PDFInfo
- Publication number
- CN110420222A CN110420222A CN201910700825.7A CN201910700825A CN110420222A CN 110420222 A CN110420222 A CN 110420222A CN 201910700825 A CN201910700825 A CN 201910700825A CN 110420222 A CN110420222 A CN 110420222A
- Authority
- CN
- China
- Prior art keywords
- rhodioside
- mesenchymal stem
- stem cell
- cell injection
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The rhodioside joint mesenchymal stem cell injection and preparation method thereof that the invention discloses a kind of for cardiomyopathy, a kind of manufacture raw material of rhodioside joint mesenchymal stem cell injection for cardiomyopathy includes umbilical cord mesenchymal stem cells, high concentration rhodioside, sodium chloride, antioxidant, cinnamyl alcohol glycosides and water for injection, and the parts by weight of the rhodioside joint mesenchymal stem cell injection manufacture raw material are umbilical cord mesenchymal stem cells 1.0-5.0 × 10^7/kg, 1-2 parts of high concentration rhodioside, 10-12 parts of sodium chloride, 3-5 parts of antioxidant.Manufacture raw material is simple and easy to get in the present invention, and manufacturing method is easy to implement, and can combine mesenchymal stem cell injection to rhodioside and carry out large batch of production；Patient can more rapidly and effectively be acted on using gadol injection by way of injection, can be worked faster to acute cardiovascular disease, can be fallen ill anxious, the cardiovascular disease of serious symptom with the control in the short time.
Description
Technical field
The present invention relates to pharmaceutical technology field, specially a kind of rhodioside for cardiomyopathy combines mescenchymal stem cell
Injection and preparation method thereof.
Background technique
Cardiovascular and cerebrovascular disease is a kind of common disease for seriously threatening the mankind's especially middle-aged and the old's health, even if application is current
Most advanced, perfect treatment means can still have 50% or more cerebrovascular accident survivor life that cannot take care of oneself completely.Heart and brain blood
Pipe disease has the characteristics that " disease incidence height, death rate height, disability rate height, high recurrence rate, complication are more "-" more than four high one ", mesh
Before, China's Patients with Cardiovascular/Cerebrovascular Diseases alreadys exceed 2.7 hundred million people.
Root of kirilow rhodiola is herbaceos perennial, is mainly grown in 1600~4000 meters of height above sea level high and cold, dry, anoxic, strong
The big area of ultraviolet light irradiation, day and night temperature, has extremely strong adaptive capacity to environment and vitality.Apply root of kirilow rhodiola very in China
Early, on the books in Tibetan medicine's Four-Volume Medical Code and Compendium of Material Medica, it is antifatigue, anti-ageing that Recent study proves that rhodioside has
Always, the multiple pharmacological effects such as immunological regulation, removing free radical.
Rhodioside has extensive pharmacological action to cardiovascular system, plays the role of activating microcirculation and removing stasis medicinal, improves microcirculation, can be with
The generation of atherosclerosis is prevented, there is apparent antiarrhythmic effect, can directly improve cardiac contractility ability, is increased outer
All resistances increase blood pressure, improve the effect of cardiac function, for this purpose, it is proposed that a kind of rhodioside for cardiomyopathy is combined
Mesenchymal stem cell injection and preparation method thereof.
Summary of the invention
The rhodioside that the purpose of the present invention is to provide a kind of for cardiomyopathy combine mesenchymal stem cell injection and
Preparation method, to solve the problems, such as to propose in background technique.
To achieve the above object, the invention provides the following technical scheme: between a kind of rhodioside joint for cardiomyopathy
Mesenchymal stem cells injection, a kind of manufacture raw material of the rhodioside joint mesenchymal stem cell injection for cardiomyopathy
It is described red including umbilical cord mesenchymal stem cells, high concentration rhodioside, sodium chloride, antioxidant, cinnamyl alcohol glycosides and water for injection
The parts by weight that red-spotted stonecrop glycosides combines mesenchymal stem cell injection manufacture raw material are umbilical cord mesenchymal stem cells 1.0-5.0 × 10^
7/kg, 1-2 parts of high concentration rhodioside, 10-12 parts of sodium chloride, 3-5 parts of antioxidant, 3-5 parts of cinnamyl alcohol glycosides, then addition is infused
It penetrates with water to 1000 parts.
A kind of preparation method of the rhodioside joint mesenchymal stem cell injection for cardiomyopathy, described one kind are used for
Cardiomyopathy rhodioside joint mesenchymal stem cell injection preparation method the following steps are included:
(1) the root of kirilow rhodiola crude extract for choosing certain mass number first is spare, and then plus water adjusts its pH value, makes its PH
Value is 9-10, root of kirilow rhodiola filtrate is then obtained by filtration, the water water temperature of the addition is set as 55-58 DEG C；
(2) pH value is adjusted to acidity followed by adjusting liquid, its pH value is 1-3 after pH value adjustment；
(3) step (2) are adjusted the root of kirilow rhodiola solution completed to dry, the drying temperature is 80-90 DEG C, with laggard
Row collects chromatographic solution；
(4) chromatographic solution concentration, alcohol precipitation, crystallization then can be obtained to the rhodioside of high concentration；
(5) umbilical cord mesenchymal stem cells of certain mass number, high concentration rhodioside, chlorine in step (4) are then weighed
Change sodium, antioxidant, cinnamyl alcohol glycosides and water for injection；
(6) then the 70-75% of the water for injection in step (5) is placed in dispensing containers, high concentration is then added
Rhodioside, sodium chloride, antioxidant, cinnamyl alcohol glycosides are put among container, are stirred to it, are carried out in whipping process to it
Heating, heating temperature are 50-55 DEG C, and remaining water for injection is added to 1000 parts after being completely dissolved, then by its benefit
It is filtered with funnel, umbilical cord mesenchymal stem cells is then added when temperature is cooled to 35-37 DEG C；
(7) solution that step (6) obtains is placed among ampulla, then carries out high-temperature sterilization；
(8) ampulla of step (7) disinfection completion is packaged the rhodioside joint for cardiomyopathy can be obtained
Mesenchymal stem cells injection.
Preferably, the high concentration rhodioside that the rhodioside needs to use concentration as 95-98%, the high concentration are red
The pH value of red-spotted stonecrop glycosides is 1-3.
Preferably, the rhodioside joint mesenchymal stem cell injection added in ampulla in the step (7) is 2-
3mL。
Preferably, sterilisation temp is 100 DEG C in the step (7), disinfecting time 20-30min.
Preferably, the umbilical cord mesenchymal stem cells are P2-P5 for umbilical cord mesenchymal stem cells.
The present invention is used and is had the advantages that
1, manufacture raw material is simple and easy to get in the present invention, and manufacturing method is easy to implement, and can combine mesenchyma to rhodioside
Stem cell injection liquid carries out large batch of production；
2, patient can more rapidly and effectively be acted on using gadol injection by way of injection, to acute
Cardiovascular disease can work faster, and can be fallen ill anxious, the cardiovascular disease of serious symptom with the control in the short time.
Specific embodiment
Technical scheme in the embodiment of the invention is clearly and completely described, it is clear that described embodiment is only
It is a part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention, ordinary skill people
Member's every other embodiment obtained without making creative work, shall fall within the protection scope of the present invention.
Embodiment one:
A kind of rhodioside joint mesenchymal stem cell injection for cardiomyopathy, it is described a kind of for the red of cardiomyopathy
The manufacture raw material that red-spotted stonecrop glycosides combines mesenchymal stem cell injection includes high concentration rhodioside, sodium chloride, antioxidant, cortex cinnamomi
The parts by weight of alcohol glycosides and water for injection, the rhodioside joint mesenchymal stem cell injection manufacture raw material are filled between umbilical cord
1.0 × 10^7/kg of matter stem cell, 1 part of high concentration rhodioside, 10 parts of sodium chloride, 3 parts of antioxidant, 3 parts of cinnamyl alcohol glycosides, with
After add and inject water to 1000 parts.
A kind of preparation method of the rhodioside joint mesenchymal stem cell injection for cardiomyopathy, described one kind are used for
Cardiomyopathy rhodioside joint mesenchymal stem cell injection preparation method the following steps are included:
(1) the root of kirilow rhodiola crude extract for choosing certain mass number first is spare, and then plus water adjusts its pH value, makes its PH
Value is 9, root of kirilow rhodiola filtrate is then obtained by filtration, the water water temperature of the addition is set as 55 DEG C；
(2) pH value is adjusted to acidity followed by adjusting liquid, its pH value is 1 after pH value adjustment；
(3) step (2) are adjusted the root of kirilow rhodiola solution completed to dry, the drying temperature is 80 DEG C, is then carried out
Collect chromatographic solution；
(4) chromatographic solution concentration, alcohol precipitation, crystallization then can be obtained to the rhodioside of high concentration；
(5) umbilical cord mesenchymal stem cells of certain mass number, high concentration rhodioside, chlorine in step (4) are then weighed
Change sodium, antioxidant, cinnamyl alcohol glycosides and water for injection；
(6) then 70% of the water for injection in step (5) is placed in dispensing containers, the red scape of high concentration is then added
Its glycosides, sodium chloride, antioxidant, cinnamyl alcohol glycosides are put among container, are stirred to it, are added in whipping process to it
Heat, heating temperature are 50 DEG C, and remaining water for injection is added to 1000 parts after being completely dissolved, it is then utilized funnel
Umbilical cord mesenchymal stem cells are then added in filtering when temperature is cooled to 35 DEG C；
(7) solution that step (6) obtains is placed among ampulla, then carries out high-temperature sterilization；
(8) ampulla completed to step (7) disinfection, which is packaged, can be obtained a kind of rhodioside connection for cardiomyopathy
Close mesenchymal stem cell injection.
The rhodioside need to use concentration for 95% high concentration rhodioside, the PH of the high concentration rhodioside
Value is 1.
The rhodioside joint mesenchymal stem cell injection added in ampulla in the step (7) is 2mL.
Sterilisation temp is 100 DEG C in the step (7), disinfecting time 20min.
The umbilical cord mesenchymal stem cells are P2-P5 for umbilical cord mesenchymal stem cells.
Embodiment two:
A kind of rhodioside joint mesenchymal stem cell injection for cardiomyopathy, it is described a kind of for the red of cardiomyopathy
The manufacture raw material that red-spotted stonecrop glycosides combines mesenchymal stem cell injection includes high concentration rhodioside, sodium chloride, antioxidant, cortex cinnamomi
The parts by weight of alcohol glycosides and water for injection, the rhodioside joint mesenchymal stem cell injection manufacture raw material are filled between umbilical cord
5.0 × 10^7/kg of matter stem cell, 2 parts of high concentration rhodioside, 12 parts of sodium chloride, 5 parts of antioxidant, 5 parts of cinnamyl alcohol glycosides, with
After add and inject water to 1000 parts.
A kind of preparation method of the rhodioside joint mesenchymal stem cell injection for cardiomyopathy, described one kind are used for
Cardiomyopathy rhodioside joint mesenchymal stem cell injection preparation method the following steps are included:
(1) the root of kirilow rhodiola crude extract for choosing certain mass number first is spare, and then plus water adjusts its pH value, makes its PH
Value is 10, root of kirilow rhodiola filtrate is then obtained by filtration, the water water temperature of the addition is set as 58 DEG C；
(2) pH value is adjusted to acidity followed by adjusting liquid, its pH value is 3 after pH value adjustment；
(3) step (2) are adjusted the root of kirilow rhodiola solution completed to dry, the drying temperature is 90 DEG C, is then carried out
Collect chromatographic solution；
(4) chromatographic solution concentration, alcohol precipitation, crystallization then can be obtained to the rhodioside of high concentration；
(5) umbilical cord mesenchymal stem cells of certain mass number, high concentration rhodioside, chlorine in step (4) are then weighed
Change sodium, antioxidant, cinnamyl alcohol glycosides and water for injection；
(6) then 75% of the water for injection in step (5) is placed in dispensing containers, the red scape of high concentration is then added
Its glycosides, sodium chloride, antioxidant, cinnamyl alcohol glycosides are put among container, are stirred to it, are added in whipping process to it
Heat, heating temperature are 55 DEG C, and remaining water for injection is added to 1000 parts after being completely dissolved, it is then utilized funnel
Umbilical cord mesenchymal stem cells are then added in filtering when temperature is cooled to 37 DEG C；
(7) solution that step (6) obtains is placed among ampulla, then carries out high-temperature sterilization；
(8) ampulla completed to step (7) disinfection, which is packaged, can be obtained a kind of rhodioside connection for cardiomyopathy
Close mesenchymal stem cell injection.
The rhodioside need to use concentration for 98% high concentration rhodioside, the PH of the high concentration rhodioside
Value is 3.
The rhodioside joint mesenchymal stem cell injection added in ampulla in the step (7) is 3mL.
Sterilisation temp is 100 DEG C in the step (7), disinfecting time 30min.
The umbilical cord mesenchymal stem cells are P2-P5 for umbilical cord mesenchymal stem cells.
Embodiment three:
A kind of rhodioside joint mesenchymal stem cell injection for cardiomyopathy, it is described a kind of for the red of cardiomyopathy
The manufacture raw material that red-spotted stonecrop glycosides combines mesenchymal stem cell injection includes high concentration rhodioside, sodium chloride, antioxidant, cortex cinnamomi
The parts by weight of alcohol glycosides and water for injection, the rhodioside joint mesenchymal stem cell injection manufacture raw material are filled between umbilical cord
2.5 × 10^7/kg of matter stem cell, 1.5 parts of parts of high concentration rhodioside, 11 parts of sodium chloride, 4 parts of antioxidant, cinnamyl alcohol glycosides 4
Part, then add and injects water to 1000 parts.
A kind of preparation method of the rhodioside joint mesenchymal stem cell injection for cardiomyopathy, described one kind are used for
Cardiomyopathy rhodioside joint mesenchymal stem cell injection preparation method the following steps are included:
(1) the root of kirilow rhodiola crude extract for choosing certain mass number first is spare, and then plus water adjusts its pH value, makes its PH
Value is 9, root of kirilow rhodiola filtrate is then obtained by filtration, the water water temperature of the addition is set as 57 DEG C；
(2) pH value is adjusted to acidity followed by adjusting liquid, its pH value is 2 after pH value adjustment；
(3) step (2) are adjusted the root of kirilow rhodiola solution completed to dry, the drying temperature is 85 DEG C, is then carried out
Collect chromatographic solution；
(4) chromatographic solution concentration, alcohol precipitation, crystallization then can be obtained to the rhodioside of high concentration；
(5) umbilical cord mesenchymal stem cells of certain mass number, high concentration rhodioside, chlorine in step (4) are then weighed
Change sodium, antioxidant, cinnamyl alcohol glycosides and water for injection；
(6) then 73% of the water for injection in step (5) is placed in dispensing containers, the red scape of high concentration is then added
Its glycosides, sodium chloride, antioxidant, cinnamyl alcohol glycosides are put among container, are stirred to it, are added in whipping process to it
Heat, heating temperature are 52 DEG C, and remaining water for injection is added to 1000 parts after being completely dissolved, it is then utilized funnel
Umbilical cord mesenchymal stem cells are then added in filtering when temperature is cooled to 36 DEG C；
(7) solution that step (6) obtains is placed among ampulla, then carries out high-temperature sterilization；
(8) ampulla completed to step (7) disinfection, which is packaged, can be obtained a kind of rhodioside connection for cardiomyopathy
Close mesenchymal stem cell injection.
The rhodioside need to use concentration for 96% high concentration rhodioside, the PH of the high concentration rhodioside
Value is 2.
The rhodioside joint mesenchymal stem cell injection added in ampulla in the step (7) is 3mL.
Sterilisation temp is 100 DEG C in the step (7), disinfecting time 25min.
The umbilical cord mesenchymal stem cells are P2-P5 for umbilical cord mesenchymal stem cells.
It although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, can be with
A variety of variations, modification, replacement can be carried out to these embodiments without departing from the principles and spirit of the present invention by understanding
And modification, the scope of the present invention is defined by the appended.
Claims (6)
1. a kind of rhodioside for cardiomyopathy combines mesenchymal stem cell injection, it is characterised in that: described one kind is used for
The manufacture raw material of the rhodioside joint mesenchymal stem cell injection of cardiomyopathy includes that umbilical cord mesenchymal stem cells, high concentration are red
Red-spotted stonecrop glycosides, sodium chloride, antioxidant, cinnamyl alcohol glycosides and water for injection, the rhodioside combine mesenchymal stem cell injection
The parts by weight for manufacturing raw material are umbilical cord mesenchymal stem cells 1.0-5.0 × 10^7/kg, 1-2 parts of high concentration rhodioside, chlorination
10-12 parts of sodium, 3-5 parts of antioxidant, 3-5 parts of cinnamyl alcohol glycosides, then add and inject water to 1000 parts.
2. a kind of preparation method of the rhodioside joint mesenchymal stem cell injection for cardiomyopathy, it is characterised in that: institute
State a kind of preparation method of rhodioside joint mesenchymal stem cell injection for cardiomyopathy the following steps are included:
(1) the root of kirilow rhodiola crude extract for choosing certain mass number first is spare, and then plus water adjusts its pH value, makes its pH value
9-10, is then obtained by filtration root of kirilow rhodiola filtrate, and the water water temperature of the addition is set as 55-58 DEG C；
(2) pH value is adjusted to acidity followed by adjusting liquid, its pH value is 1-3 after pH value adjustment；
(3) step (2) are adjusted the root of kirilow rhodiola solution completed to dry, the drying temperature is 80-90 DEG C, is then received
Collect chromatographic solution；
(4) chromatographic solution concentration, alcohol precipitation, crystallization then can be obtained to the rhodioside of high concentration；
(5) then weigh the umbilical cord mesenchymal stem cells of certain mass number in step (4), high concentration rhodioside, sodium chloride,
Antioxidant, cinnamyl alcohol glycosides and water for injection；
(6) then the 70-75% of the water for injection in step (5) is placed in dispensing containers, the red scape of high concentration is then added
Its glycosides, sodium chloride, antioxidant, cinnamyl alcohol glycosides are put among container, are stirred to it, are added in whipping process to it
Heat, heating temperature are 50-55 DEG C, and remaining water for injection is added to 1000 parts after being completely dissolved, is then utilized
Funnel filtering, is then added umbilical cord mesenchymal stem cells when temperature is cooled to 35-37 DEG C；
(7) solution that step (6) obtains is placed among ampulla, then carries out high-temperature sterilization；
(8) ampulla completed to step (7) disinfection, which is packaged can be obtained, combines mesenchyma for the rhodioside of cardiomyopathy
Stem cell injection liquid.
3. a kind of rhodioside for cardiomyopathy according to claim 1 combines mesenchymal stem cell injection, special
Sign is: the high concentration rhodioside that the rhodioside needs to use concentration as 95-98%, the high concentration rhodioside
PH value is 1-3.
4. a kind of preparation of rhodioside joint mesenchymal stem cell injection for cardiomyopathy according to claim 2
Method, it is characterised in that: the rhodioside joint mesenchymal stem cell injection added in ampulla in the step (7) is 2-
3mL。
5. a kind of preparation of rhodioside joint mesenchymal stem cell injection for cardiomyopathy according to claim 2
Method, it is characterised in that: sterilisation temp is 100 DEG C in the step (7), disinfecting time 20-30min.
6. a kind of rhodioside for cardiomyopathy according to claim 1 combines mesenchymal stem cell injection, special
Sign is: the umbilical cord mesenchymal stem cells are P2-P5 for umbilical cord mesenchymal stem cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910700825.7A CN110420222A (en) | 2019-07-31 | 2019-07-31 | A kind of rhodioside joint mesenchymal stem cell injection and preparation method thereof for cardiomyopathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910700825.7A CN110420222A (en) | 2019-07-31 | 2019-07-31 | A kind of rhodioside joint mesenchymal stem cell injection and preparation method thereof for cardiomyopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110420222A true CN110420222A (en) | 2019-11-08 |
Family
ID=68411744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910700825.7A Pending CN110420222A (en) | 2019-07-31 | 2019-07-31 | A kind of rhodioside joint mesenchymal stem cell injection and preparation method thereof for cardiomyopathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110420222A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101130561A (en) * | 2007-08-10 | 2008-02-27 | 成都诺迪康生物制药有限公司 | Method for producing salidroside and injection containing the same |
| CN103087984A (en) * | 2011-11-01 | 2013-05-08 | 北京清美联创干细胞科技有限公司 | Traditional Chinese medicinal composition having mesenchymal stem cell propagation promoting effect, and its applications |
| CN109694851A (en) * | 2019-01-16 | 2019-04-30 | 吉林省拓华生物科技有限公司 | A kind of inducing composition of human mesenchymal stem cell, induction differentiation culture solution and its external evoked methods and applications |
-
2019
- 2019-07-31 CN CN201910700825.7A patent/CN110420222A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101130561A (en) * | 2007-08-10 | 2008-02-27 | 成都诺迪康生物制药有限公司 | Method for producing salidroside and injection containing the same |
| CN103087984A (en) * | 2011-11-01 | 2013-05-08 | 北京清美联创干细胞科技有限公司 | Traditional Chinese medicinal composition having mesenchymal stem cell propagation promoting effect, and its applications |
| CN109694851A (en) * | 2019-01-16 | 2019-04-30 | 吉林省拓华生物科技有限公司 | A kind of inducing composition of human mesenchymal stem cell, induction differentiation culture solution and its external evoked methods and applications |
Non-Patent Citations (7)
| Title |
|---|
| JINPING ZHANG ET AL.: ""Salidroside protects cardiomyocyte against hypoxia-induced death:A HIF-1 α -activated and VEGF-mediated pathway"", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 * |
| 侯宗柳: "《围产期成体干细胞基础与临床应用》", 31 October 2016, 云南科技出版社 * |
| 光雪峰 等: "《心血管疾病基础与临床新进展 2014》", 31 October 2014, 云南科技出版社 * |
| 王雨 等: ""中药及其提取物诱导脐带间充质干细胞分化的研究进展"", 《时珍国医国药》 * |
| 田金鑫 等: ""中药调控干细胞移植心肌梗死的作用及机制"", 《中国中医急症》 * |
| 邱久文 等: ""大株红景天注射液抗大鼠急性心肌缺血作用"", 《中国现代中药》 * |
| 黄世敬: "《抗抑郁中药良方》", 29 February 2016, 金盾出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11357814B2 (en) | Application of Sarcococca vagans, Chinese medicinal ointment for treating skin disease, preparation method and application thereof | |
| CN104042893A (en) | Traditional Chinese medicine preparation for treating gout and preparation method of traditional Chinese medicine preparation | |
| CN101979020B (en) | Chinese medicinal preparation for treating high blood pressure | |
| CN104957616A (en) | Health-care food having function of relieving visual fatigue | |
| CN110420222A (en) | A kind of rhodioside joint mesenchymal stem cell injection and preparation method thereof for cardiomyopathy | |
| CN103356697A (en) | Stem cell preparation and oral fluid prepared therefrom | |
| CN109331043A (en) | A kind of pharmaceutical composition and preparation method thereof for treating ulcer malignant boil furuncle | |
| CN1268385C (en) | Chinese medicinal for epilepsy and insanity | |
| CN104474015B (en) | A kind of drug and preparation method thereof for blood fat-reducing blood pressure-decreasing | |
| CN100574787C (en) | A kind of Chinese medicine composition of orally taken for curing glaucoma | |
| CN101869631B (en) | Toxicant elimination medicament for eyes | |
| CN102670851B (en) | Selenium-enriched traditional Chinese medicinal herb eye refreshing drops | |
| CN101612288B (en) | Traditional Chinese medicine for treating diabetic retinopathy | |
| CN101301304A (en) | Chinese medicinal composition for treating ischemic stroke and preparation thereof | |
| CN101199766B (en) | Medicament for treating epileps | |
| CN109464602A (en) | A kind of Traditional Chinese medicine plaster dressing and preparation method thereof improving eyes visual fatigue | |
| CN101313982B (en) | Traditional Chinese medicine onion slurry, preparing method and uses thereof | |
| CN103585431B (en) | Traditional Chinese medicine composition for curing type I diabetes mellitus | |
| CN102119971B (en) | Traditional Chinese medicine for treating coronary heart disease | |
| CN101337005A (en) | Cataract eliminating eyesight recovery pill | |
| CN105748583A (en) | An encapsulated vagina cleaning liquid and a preparing process thereof | |
| CN104800664A (en) | Medicine for treating amblyopia disease | |
| CN104587139A (en) | Pharmaceutical composition for treating juvenile myopia and application of pharmaceutical composition | |
| CN102114208A (en) | Traditional Chinese medicine for treating diabetes and preparation method thereof | |
| CN101190247B (en) | Traditional Chinese medicine liquid for treating burn and scald |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191108 |